West Pharmaceutical Servs Q1 2024 Adj EPS $1.56 Beats $1.26 Estimate, Sales $695.400M Beat $670.303M Estimate
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical Servs (WST) reported Q1 2024 adjusted EPS of $1.56, surpassing the $1.26 estimate, with sales of $695.4M also beating the $670.303M forecast. Despite these beats, both earnings and sales saw a decrease compared to the same period last year.
April 25, 2024 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
WST reported a strong Q1 2024 performance with earnings and sales exceeding estimates, despite a year-over-year decline.
Beating both earnings and sales estimates typically has a positive impact on a company's stock price in the short term. However, the year-over-year decline in both metrics might temper investor enthusiasm, suggesting a cautious optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100